Valneva SE (VALN) surged 7.55% during intraday trading on Wednesday, driven by positive final data from a mid-stage study of its Lyme disease vaccine candidate, VLA15, developed in collaboration with Pfizer.

The study showed that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups, six months after participants received the third yearly booster dose. The safety profile also remained favorable, with no concerns identified by the independent Data Monitoring Committee.

Analysts noted that VLA15 is the furthest-advanced Lyme disease vaccine in development, and the data increases confidence in the success of the upcoming late-stage trial, expected in the first half of 2026. This development positions Valneva as a key player in addressing the unmet need for a human Lyme disease vaccine.